Vancouver, British Columbia - TheNewswire - June 24, 2020 - Cava Healthcare Inc. ("Cava" or the "Company") is pleased to announce the appointment of Mr. Theo Warkentin as Director and Chief Executive Officer (CEO).
Mr. Peter Field will step down as CEO and President. The Company thanks Mr. Field for his many contributions and is looking forward to working with him as a member of the Board of Directors.
As CEO of Cava, Mr. Warkentin will be focused on maximizing stakeholder value through a mandate to create strong internal research and development programs that enable strategic commercial partnerships and to identify funding sources to enhance the Cava business model.
Mr. Warkentin holds a Bachelor of Science degree from the University of Victoria in Economics and Chemistry. He has more than 20 years' experience in capital formation, venture capital funding and emerging company development. He has created and managed many technology companies in Canada and the USA, including those in the clean energy and healthcare sectors. Theo is an entrepreneur who continuously pursues opportunities to take projects from initial visualization to commercialization.
Theo states "By focusing on growth and innovation, we intend to establish a formidable healthcare corporation that creates value for Cava shareholders".
For further information, please contact Theo Warkentin at firstname.lastname@example.org or (604) 370-1757.
On Behalf of the Board of Directors
Dr. Wilfred Jefferies
CSO and Director
CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE
Chronic and acute inflammation and poor immune function are at the core of developing disease. Cava is addressing this unmet healthcare challenge through isolation and characterization of novel compounds from medicinal plant extraction, creation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company's current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
- Not for dissemination in the United States -
Copyright (c) 2020 TheNewswire - All rights reserved.